Immuneering Corp (IMRX)
1.47
0.00 (0.00%)
USD |
NASDAQ |
May 21, 10:49
Immuneering Cash from Financing (Quarterly): 0.9799M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.9799M |
December 31, 2023 | 0.0078M |
September 30, 2023 | 0.0214M |
June 30, 2023 | 28.17M |
March 31, 2023 | 0.2394M |
December 31, 2022 | -0.1847M |
September 30, 2022 | -0.0172M |
June 30, 2022 | 0.0278M |
March 31, 2022 | 0.1931M |
Date | Value |
---|---|
December 31, 2021 | 0.0075M |
September 30, 2021 | 118.49M |
June 30, 2021 | 25.77M |
March 31, 2021 | 0.00 |
December 31, 2020 | 36.98M |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.9983M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1847M
Minimum
Dec 2022
118.49M
Maximum
Sep 2021
12.45M
Average
0.0278M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
Geron Corp | 147.80M |
SELLAS Life Sciences Group Inc | 26.65M |
Elicio Therapeutics Inc | 11.02M |
ADMA Biologics Inc | -1.447M |
Outlook Therapeutics Inc | 56.14M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -15.49M |
Cash from Investing (Quarterly) | 21.39M |
Free Cash Flow | -50.39M |
Free Cash Flow Per Share (Quarterly) | -0.5287 |
Free Cash Flow Yield | -117.6% |